Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.62 |
| ▸ | PPARG | P37231 | 3/20 | 0.62 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | THRA | P10827 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4180280 | 0.90 | PPARA (0.58) | PPARAPPARGCNR1CNR2PLA2G4B | |
| SCHEMBL10807628 | 0.87 | PPARA (0.64) | PPARAPPARGSMPD1CNR1CNR2 | |
| SCHEMBL4146552 | 0.85 | PPARA (0.60) | PPARAPPARGSMPD1 | |
| SCHEMBL7942130 | 0.85 | PPARA (0.60) | PPARAPPARGSMPD1 | |
| SCHEMBL26997160 | 0.84 | PPARA (0.67) | PPARAPPARG | |
| SCHEMBL17509797 | 0.84 | PPARA (0.68) | PPARAPPARGCNR1CNR2PLA2G4B | |
| SCHEMBL17509789 | 0.84 | PPARA (0.68) | PPARAPPARGCNR1CNR2PLA2G4B | |
| SCHEMBL17509804 | 0.84 | PPARA (0.68) | PPARAPPARGCNR1CNR2PLA2G4B | |
| SCHEMBL17509791 | 0.84 | PPARA (0.68) | PPARAPPARGCNR1CNR2PLA2G4B | |
| SCHEMBL17509779 | 0.84 | PPARA (0.68) | PPARAPPARGCNR1CNR2PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143609-A1 | LIQUID CRYSTAL COMPOSITIONS AND THEIR USE IN LIQUID CRYSTAL DEVICES | IPS ALPHA SUPPORT CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143609-A1 | LIQUID CRYSTAL COMPOSITIONS AND THEIR USE IN LIQUID CRYSTAL DEVICES | IPS ALPHA SUPPORT CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143609-A1 | LIQUID CRYSTAL COMPOSITIONS AND THEIR USE IN LIQUID CRYSTAL DEVICES | GTF3C3, CCR3, OR10J3 | PPARA 4802/4885PPARG 4661/4885SMPD1 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.